Phase 2 vs Phase 3 — Hematology Deal Valuation Comparison

Phase 2 Median Upfront

$604M

Total: $3.0B

Phase 3 Median Upfront

$2.0B

Total: $6.8B

Stage Premium

129%

Phase 3 premium over Phase 2

Phase 2 Royalties

8.5%-16%

vs Phase 3: 11.7%-21.3%

Model Your Deal

Market Analysis

The Phase 2 to Phase 3 transition in hematology represents a significant value inflection point. Phase 3 deals carry a median total deal value of $6.8B compared to $3.0B at Phase 2, a 129% premium reflecting clinical de-risking. Upfront payments increase from $604M to $2.0B.

Deal structures shift as assets advance. Phase 2 deals allocate 20% to upfront and 80% to milestones, while Phase 3 deals shift to 29%/71%. Development milestones move from $500M to $485M, and royalty rates evolve from 8.5%-16% to 11.7%-21.3%.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the deal value premium from Phase 2 to Phase 3 in hematology?

Phase 3 hematology deals command a 129% premium over Phase 2 in total deal value ($6.8B vs $3.0B). Upfronts increase from $604M to $2.0B, reflecting the de-risking value of clinical progression.

How do deal structures differ between Phase 2 and Phase 3 in hematology?

Phase 2 deals are more milestone-weighted (80% milestones), reflecting higher clinical risk. Phase 3 deals shift toward higher upfront allocations (29% upfront) as clinical de-risking reduces the need for contingent milestone structures.

When is the optimal time to license a hematology asset?

The optimal licensing window depends on strategic priorities. Phase 2 assets offer lower entry cost for licensees, while Phase 3 assets provide more certainty. The 129% premium from Phase 2 to Phase 3 reflects the value created by clinical data, making the transition point critical for deal timing.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included